Haritaki is the dried fruit of Terminalia chebula, a tree used in Ayurvedic preparations and one of the three fruits in Triphala. Researchers have tested specific haritaki extracts in small human studies. The viral claims, like detox and pineal gland “decalcification,” outrun that evidence.
Below, you’ll see what the studies tested, what they can’t tell you, what safety sources say, and how to read a label, so you can judge a product yourself.
Key takeaways
- Haritaki is Terminalia chebula fruit. Some standards define it as the pericarp only.
- Human studies exist, but they’re small and test specific extracts.
- Traditional use and lab chemistry don’t prove benefit in people.
- You can’t compare milligrams of extract with grams of powder.
- Safety data are incomplete. Two WHO publications disagree on breastfeeding and children.
What is haritaki?
Kew lists the accepted name as Terminalia chebula Retz., family Combretaceae. Haritaki, harad, kadukkai, black myrobalan, chebulic myrobalan and inknut all point at the fruit. A common name doesn’t tell you the species, the maturity or the preparation.
| Term | What it means |
|---|---|
| Haritaki | Sanskrit and Ayurvedic name for the fruit or its preparations |
| Harad | Hindi and regional market name |
| Kadukkai | Tamil name, also printed on products |
| Inknut, black or chebulic myrobalan | English common names, not product specifications |
| Triphala | Haritaki plus bibhitaki (T. bellirica) plus amalaki (Phyllanthus emblica) |
Any Triphala study tests three fruits at once, so you can’t hand its results to haritaki alone.
Which part of the fruit?
The Ayurvedic Pharmacopoeia of India defines haritaki as the pericarp of the mature fruit. WHO’s 2010 regional manual describes a seedless powder. One reading of classical texts says whole fruit, unless a formula says otherwise. All three are legitimate in their own context. None is the single correct answer.
Part still changes what you’re swallowing. A 2024 analysis measured 12 selected compounds in the tested fruit and found 148.86 mg/g in the exocarp, 96.14 mg/g in the mesocarp and 18.64 mg/g in the endocarp plus seed. Those are totals for chosen analytes in one sample. They’re not total tannins and they don’t rank potency. They do show that “haritaki” on a label doesn’t say which material was tested.
Drying matters too. In the same study, 28 days of sunlight drying lowered several hydrolysable tannins while some simpler phenolic acids rose. It was one location and one protocol, so don’t read it as “sun-dried is bad.”
The seven classical names
Texts list Vijaya, Rohini, Putana, Amrita, Abhaya, Jivanti and Chetaki. Nobody has settled how these map to modern botanical varieties or commercial grades. If a seller advertises “Vijaya grade,” ask what that means and who verified it.
Haritaki benefits: what the evidence supports
Most human trials used branded extracts, not kitchen-cupboard powder. Read the limit column first.
| Topic and study | What was tested | Finding and limit |
|---|---|---|
| Asymptomatic hyperuricemia (Usharani 2016) | 110 enrolled, 88 finished. AyuFlex extract, 500 mg twice daily, 24 weeks. | Uric acid fell about 1.34 mg/dL. Febuxostat lowered it about 4.25 mg/dL. Participants didn’t have gout. |
| Activity-related knee discomfort (Lopez 2017) | 105 overweight adults, 35 to 70, no diagnosed osteoarthritis. 250 or 500 mg twice daily, 12 weeks. | Authors reported changes in discomfort and walking. One product, self-reported outcomes, company support. |
| Hemorrhoid symptoms (Andarkhor 2019) | 104 people, capsules four times daily, four weeks. | Pain, constipation and size improved. Bleeding days didn’t differ. Single center, no replication. |
| Type 2 diabetes vascular markers (Pingali 2020) | 60 adults, 250 or 500 mg twice daily, 12 weeks. | Endothelial and risk markers changed. Markers aren’t cardiovascular events. |
| Prediabetes (Sombattera 2022) | 80 people, 2 g/day fruit water extract, eight weeks. | Fasting glucose was lower only in an overweight subgroup. People on glucose-affecting drugs were excluded. |
| Skin appearance (Chakkalakal 2023) | 38 healthy women, Synastol TC 250 mg twice daily, eight weeks. | Sebum, redness and wrinkle appearance changed. Cosmetic markers, not skin disease. |
| Gut microbiome (2024) | 43 women, 250 mg twice daily, eight weeks. | Microbiome, fatty-acid and bile-acid shifts. Nobody showed better digestion. |
| Experimental pain (two studies) | 12 healthy men each, 1,000 mg once. | A lab pain response says nothing about chronic pain or arthritis. |
The studies are narrow, short and mostly product-specific. WHO’s 2009 monograph said clinical data supported no uses at that time. Later trials added narrow signals, nothing broad.
Digestion and constipation
Laxative use is traditional and documented. Modern proof is thin. The one hemorrhoid trial wasn’t a constipation study, and multi-ingredient formulas containing senna can’t isolate haritaki. The sources reviewed contain no robust single-ingredient constipation trial. That describes those sources, not every study ever run.
Antioxidants
Haritaki is rich in polyphenols such as chebulagic acid, chebulinic acid, gallic acid, ellagic acid and corilagin. That’s chemistry, and a test tube result doesn’t show that a supplement prevents disease in a person.
Mouth rinses are a different thing
Several small trials tested haritaki as a rinse, not a swallowed product. Gupta 2014 gave 78 people a 10% rinse twice daily for two weeks and compared it with chlorhexidine and saline. Both active rinses improved periodontal indices, with no significant difference between them. A 2016 study of 60 high-caries-risk children measured salivary S. mutans and pH for 90 minutes after rinsing. That’s a short-term bacterial count, not fewer cavities.
“No significant difference” doesn’t mean “equivalent.” And none of this validates swallowing powder for systemic effects.
A 2026 halitosis paper shows why you read tables, not abstracts. Its abstract says the rinse beat chlorhexidine. Its own tables give post-treatment between-group p-values of 0.407 and 0.677. Its conclusion says there was no significant difference. Those statements can’t all be true. Both groups of 15 improved from baseline, and that’s as far as the tables go.
Is haritaki a nootropic?
A 2025 randomized trial gave 100 adults aged 40 to 65 with subjective memory complaints 300 mg daily of LN19184, or placebo, for 120 days. LN19184 combines Boswellia serrata and T. chebula extracts. The authors reported better scores on several memory tests, sleep and serum BDNF. 87 people finished. The funder makes the product.
You can’t say “haritaki improves memory” from this. It tested two herbs together, in people without a diagnosed disorder, in a pilot that needs replication. A later 2026 paper tested the same blend in cells and rats. That’s preclinical only.
Pineal gland, kidney and detox claims
The sources reviewed show no human clinical evidence that haritaki decalcifies the pineal gland or improves its function. Antioxidant chemistry doesn’t get you there. They also show no human evidence that it cleanses the kidneys. If you have kidney disease, ask your clinician before taking any supplement, because interaction data are missing, not because haritaki is proven harmful.
Is haritaki safe? Side effects and who should ask first
This isn’t medical advice. Talk to a clinician or pharmacist before you start.
The most plausible effects are digestive. Think loose stools, diarrhea, cramps and nausea. In a small open-label seasonal-regimen study, a first 6 g dose of haritaki with salt caused severe purging and vomiting in pilot participants, so researchers cut it to 3 g. That’s one study, not a dosing rule. Small trials with few serious events can’t establish long-term safety.
WHO disagrees with itself
| Source | Pregnancy | Breastfeeding | Children |
|---|---|---|---|
| WHO monograph, 2009 | Not recommended | Not recommended | Not recommended under 12 |
| WHO regional manual, 2010 | Do not prescribe | Calls nursing infant safe | Gives a child dose |
The 2009 text says safety data were lacking. The 2010 manual doesn’t present evidence that fills that gap. The disagreement proves neither harm nor safety. So don’t pick the reassuring line. If you’re pregnant, nursing, or thinking of giving it to a child, don’t self-treat.
Medications
The sources reviewed contain no human interaction studies. A rat study suggests possible CYP2C19 and CYP2E1 effects. No human interaction has been shown. The glucose trials excluded people on glucose-affecting drugs, so additive effects haven’t been tested. If you take regular medication, ask a pharmacist first.
Contaminants
A 2008 JAMA survey found heavy metals in some Ayurvedic products. It wasn’t a haritaki survey, so it doesn’t give a contamination rate for haritaki. It’s a reason to ask for a batch-specific certificate of analysis.
Powder, capsules and extract
These aren’t interchangeable. The API lists 3 to 6 g of powder. WHO’s 2009 monograph lists 3 to 9 g of crude drug as a decoction. Trials use hundreds of milligrams of extract. You can’t convert between them, because solvent, extraction ratio and assay change what’s in the dose. No universal evidence-based dose exists, so I won’t give you one. For what capsule listings actually print, see our haritaki capsules guide.
One retail listing for “haritaki powder” gave its grade as “Food / Cosmetic,” left the COA field empty, and said the product was for external use. That’s one listing, not a verdict on the category. It does show why you check the exact product’s intended route.
How to read a haritaki label
Keep four questions apart. Identity: is it the named species and part? Purity: is it free of excess foreign matter and contaminants? Composition: which markers, at what level? Clinical evidence: did this exact formulation improve a meaningful outcome? A certificate answers the first three at best. Only a trial answers the fourth.
- It names Terminalia chebula.
- It states plant part and preparation.
- It says powder, extract or blend.
- It gives milligrams per serving.
- It lists solvent, ratio and standardization basis.
- It gives a marker assay and specification.
- It offers a batch-specific COA from a named lab.
- It reports heavy-metal and contaminant testing.
- It states origin and organic status. Treat these as context, not proof.
Take this invented example (example only): “500 mg capsule, 10:1 aqueous extract, standardized to 20% chebulagic plus chebulinic acids.” It gives you a marker level. It doesn’t say that 500 mg equals 5 g of powder, and it doesn’t say the capsule works.
Standards differ too. The API sets limits on foreign matter (1% or less), total ash and acid-insoluble ash (5% or less each) and extractive values. USP defines pericarp and requires at least 15% hydrolysable tannins as chebulagic plus chebulinic acids. Different scope, different assays. Don’t compare the numbers as one potency scale. Also, a blend’s markers can differ again: the memory trial’s product was standardized to gallic acid, ellagic acid and amyrins.
Fakes and look-alikes
Researchers have tested look-alike Terminalia species and immature fruit with DNA and chemical fingerprints. Morphology, DNA and chemistry answer related but different questions. Nobody has measured how much of the retail market is substituted, so treat substitution as a documented problem with no known rate.
Haritaki vs Triphala
Triphala is haritaki, bibhitaki and amalaki together. Studies on it test the mix. A rat study of a seven-herb formula found that co-ingredients raised plasma exposure to haritaki phenolics and slowed their breakdown by gut bacteria. That’s a rat finding, not proof of a better formula. It does mean a multi-herb blend isn’t a simple sum of its parts.
FAQ
Is haritaki safe to take daily? Nobody has established long-term safety. Ask a clinician.
Can I take it with medication? Human interaction data are lacking. Ask a pharmacist.
Is it the same as Triphala? No. Triphala contains haritaki and two other fruits.
Does it help the pineal gland? The sources reviewed show no human evidence that it does. See the full evidence on haritaki and the pineal gland.
Bottom line
Haritaki is a well-documented traditional fruit with real chemistry and a handful of small, product-specific human trials. The evidence doesn’t make it a detox, a nootropic or a treatment. Before you buy, find out what the product actually is: species, part, form, dose and a batch certificate. If a page can’t tell you, don’t trust the claims on it.
What we don’t know
- How classical varieties map to modern botany
- How much retail product is substituted
- Whether fruit parts and extracts are equivalent
- Human medication interactions
- Whether the pineal and kidney claims have any human support
Sources
- Kew POWO: Terminalia chebula
- Ayurvedic Pharmacopoeia of India, Part I, Vol. I
- WHO Monographs, Vol. 4 (2009)
- WHO Traditional Herbal Remedies (2010)
- USP-NF Terminalia Chebula Fruit
- Xu et al., 2024, Molecules
- Ratha et al., 2013, varieties review
- Usharani et al., 2016
- Lopez et al., 2017
- Andarkhor et al., 2019
- Pingali et al., 2020
- Sombattera et al., 2022
- Chakkalakal et al., 2023
- 2024 Synastol TC microbiome study
- Salter et al., 2025, Frontiers in Nutrition
- Gupta et al., 2014
- Palit et al., 2016
- Divyadharshini et al., 2026
- Gao et al., 2016, J Ethnopharmacology
- Rat CYP study, 2020
- Seasonal regimen trial, 2021
- Saper et al., JAMA 2008
